Global Experts in MSC Clinical Translation to Advise Ebstrocel™ Regulatory and Clinical Development and Guide Expansion of CORDStrom Product Opportunities BOCA RATON, Fla., July 30, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a late-stage biotechnology company focused on inflammation and immunology, today announced the formation of a Scientific Advisory Board ("SAB") to support the late-stage development of Ebstrocel™ for recessive dystrophic epidermolysis bullosa ("RDEB") and g ...